Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up
AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.
Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Pizzie - CFO Ari Maizel - EVP and Head, Commercial Mark Jacobson - Chief Operating Officer Conference Call Participants Jason Gerberry - Bank of America Leonid Timashev - RBC Capital Markets Charles Duncan - Cantor Fitzgerald Cerena Chen - Wells Fargo David Amsellem - Piper Sandler Marc Goodman - Leerink Partners Joseph Thome - TD Cowen Myles Minter - William Blair Poorna Kannan - Needham & Company Joel Beatty - Baird Graig Suvannavejh - Mizuho Securities Matt Kaplan - Ladenburg Thalmann Operator Good morning, and welcome to the Axsome Therapeutics Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to loss of $1.32 per share a year ago.
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Bargain Stocks to Buy in a Market That's Priced for Perfection
Yes, bargains can still be found in the stock market.
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?
AXSM's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. Stiff competition in the target market remains a concern.
1 Under-the-Radar Biotech Stock to Buy and Hold
Axsome Therapeutics' revenue is growing rapidly. The company's pipeline should lead to many new approvals and label expansions.
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025.
Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome (AXSM) Banks on Auvelity & Sunosi to Fuel Growth
Axsome's (AXSM) depression drug, Auvelity, is driving the company's top line. The acquisition of Sunosi from Jazz diversifies its commercial opportunity.
